Immunopotentiative composition

Patent metadata

Field	Value
Publication number	US-9439962-B2
Application number	US-201615000869-A
Country	US
Kind code	B2
Filing date	Jan 19, 2016
Priority date	Jul 3, 2002
Publication date	Sep 13, 2016
Grant date	Sep 13, 2016

Abstract

Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods.
The compositions of the present invention that inhibits the function of PD-1, PD-L1, PD-L2 are useful for cancer or infection treatment.

First claim

The invention claimed is:

1. A method of treating a tumor in a human in need thereof comprising administering to the human an effective amount of an anti-PD-L1 monoclonal antibody that inhibits an interaction between PD-1 and PD-L1 in combination with an effective amount of a chemotherapeutic drug.

2. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody comprises a heavy chain constant region of an IgG2, IgG3, or IgG4 isotype.

3. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody comprises a heavy chain constant region of an IgG1 isotype.

4. The method of claim 1 , wherein the tumor is a solid tumor.

5. The method of claim 1 , wherein the anti-PD-L1 monoclonal antibody suppresses growth of the tumor or metastasis of the tumor.

6. The method of claim 1 , wherein the tumor is one or more selected from a carcinoma, a squamous carcinoma, an adenocarcinoma, a sarcoma, a leukemia, a neuroma, a melanoma, and a lymphoma.

7. The method of claim 6 , wherein the squamous carcinoma is in the cervical canal, eyelid, tunica conjunctiva vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, or gullet.

8. The method of claim 6 , wherein the adenocarcinoma is in the prostate, small intestine, endometrium, cervical canal, large intestine, lung, pancreas, gullet, intestinum rectum, uterus, stomach, mammary gland, or ovary.

9. The method of claim 1 , wherein the tumor is melanoma.

10. The method of claim 1 , wherein the tumor is in the lung.

11. The method of claim 1 , wherein the tumor is in the urinary bladder.

12. The method of claim 1 wherein the tumor expresses PD-L1.

13. The method of claim 1 , wherein the chemotherapeutic drug comprises an alkylating agent, a nitrosourea agent, an antimetabolite, an antitumor antibiotic, an alkaloid derived from a plant, a topoisomerase inhibitor, a hormone therapy medicine, a hormone antagonist, an aromatase inhibitor, a P-glycoprotein inhibitor, or a platinum complex derivative.

14. The method of claim 1 , wherein the chemotherapeutic drug comprises a platinum complex derivative.

15. The method of claim 10 , wherein the chemotherapeutic drug comprises an alkylating agent, a nitrosourea agent, an antimetabolite, an antitumor antibiotic, an alkaloid derived from a plant, a topoisomerase inhibitor, a hormone therapy medicine, a hormone antagonist, an aromatase inhibitor, a P-glycoprotein inhibitor, or a platinum complex derivative.

16. The method of claim 13 , wherein the chemotherapeutic drug is administered to the human together with the anti-PD-L1 monoclonal antibody.

17. A method of suppressing tumor growth in a human in need thereof comprising administering to the human an effective amount of an anti-PD-L1 monoclonal antibody in combination with an effective amount of a chemotherapeutic drug, wherein the anti-PD-L1 monoclonal antibody and the chemotherapeutic drug suppress the tumor growth in the human and wherein the anti-PD-L1 monoclonal antibody inhibits and interaction between PD-1 and PD-L1 in suppressing the tumor growth.

18. The method of claim 17 , wherein the tumor is a solid tumor.

19. The method of claim 18 , wherein tumor metastasis is suppressed.

20. The method of claim 17 , wherein the tumor is one or more selected from a carcinoma, a squamous carcinoma, an adenocarcinoma, a sarcoma, a leukemia, a neuroma, a melanoma, and a lymphoma.

21. The method of claim 20 , wherein the squamous carcinoma is in the cervical canal, eyelid, tunica conjunctiva, vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, or gullet.

22. The method of claim 20 , wherein the squamous carcinoma is in the lung.

23. The method of claim 20 , wherein the adenocarcinoma is in the prostate, small intestine, endometrium, cervical canal, large intestine, lung, pancreas, gullet, intestinum rectum, uterus, stomach, mammary gland, or ovary.

24. The method of claim 17 , wherein the tumor is melanoma.

25. The method of claim 17 , wherein the tumor is in the lung.

26. The method of claim 17 , wherein the tumor is in the urinary bladder.

27. The method of claim 17 , wherein the tumor expresses PD-L1.

28. The method of claim 17 , wherein the chemotherapeutic drug comprises an alkylating agent, a nitrosourea agent, an antimetabolite, an antitumor antibiotic, an alkaloid derived from a plant, a topoisomerase inhibitor, a hormone therapy medicine, a hormone antagonist, an aromatase inhibitor, a P-glycoprotein inhibitor, or a platinum complex derivative.

29. A method of treating a lung cancer in a human in need thereof comprising administering to the human an effective amount of an anti-PD-L1 monoclonal antibody of an IgG1 isotype that inhibits an interaction between PD-1 and PD-L1 in combination with an effective amount of a platinum complex derivative, wherein the administering treats the lung cancer.

30. The method of claim 17 , wherein the anti-PD-L1 monoclonal antibody is of an IgG1 isotype.

Assignees

• Ono Pharmaceutical Co
• Honjo Tasuku

Inventors

• Honjo Tasuku
• Minato Nagahiro
• Iwai Yoshiko
• Shibayama Shiro

Classifications

• A61P31/18

  for HIV · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title